| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone | Frank Vinluan | 09/06/19 | National |
| SMA, Migraine Data Lead Neuro Highlights from AAN Meeting | Ben Fidler | 05/07/19 | National |
| How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy | Ben Fidler | 04/15/19 | National |
| Genetic Medicine: FDA OKs 2nd Cancer Drug That Targets DNA, Not Tissues | Ben Fidler | 11/26/18 | National |
| Eyeing Approval, Pfizer Touts Tafamidis Study, but Details Lacking | Alex Lash | 08/27/18 | New York |
| Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning | Frank Vinluan | 06/01/18 | Indiana |
| FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses | Frank Vinluan | 04/23/18 | Indiana |
| Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More | Alex Lash | 04/20/18 | National |
| Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms | Frank Vinluan | 04/19/18 | Indiana |
| For More Lung Cancer Patients, the Promise of No Chemo Looms Larger | Alex Lash | 04/16/18 | National |
| Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks | Ben Fidler | 03/23/18 | National |
| Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles | Ben Fidler | 01/25/18 | Boston |
| Xconomy Bookclub: “Troublemakers” Charts the Birth of Silicon Valley | Angela Shah | 01/05/18 | National |
| Bio Roundup: Trials to Watch, Mega Deals, Video Game Therapy & More | Ben Fidler | 12/08/17 | Boston |
| Bio Roundup: Migraine Data, Cancer Drug Combos, Azar Hearing & More | Frank Vinluan | 12/01/17 | National |
| With Good Data From Rival Migraine Drugs, Doctors Foresee Price Headaches | Ben Fidler | 11/29/17 | San Francisco |
| Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOs & More | Frank Vinluan | 11/03/17 | National |
| Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission | Frank Vinluan | 08/30/17 | Indiana |
| Will Merck Seek FDA Filing For Heart Drug After Lackluster Results? | Ben Fidler | 08/29/17 | New York |
| Portola Pharmaceuticals’ Drug to Prevent Blood Clots Wins FDA Nod | Frank Vinluan | 06/23/17 | San Francisco |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| With $145M Buyout, River Vision’s Plan For Stalled Roche Drug Pays Off | Ben Fidler | 05/08/17 | New York |
| FDA Nixes Lilly, Incyte RA Drug, Seeks More Dosing and Safety Data | Frank Vinluan | 04/14/17 | Indiana |
| With Fresh Pneumonia Data, Paratek To Seek 2018 Antibiotic Approval | Ben Fidler | 04/03/17 | Boston |
| With New Data, Amgen Promises Refund If Cholesterol Drug Doesn’t Work | Ben Fidler | 03/17/17 | San Francisco |
| Despite FDA Delay, Advocates Hopeful for New Genentech MS Drug | Frank Vinluan | 12/21/16 | San Francisco |
| War, Surgery, and Cancer Vaccines: Meet San Antonio’s George Peoples | David Holley | 08/19/16 | Texas |
| After Zafgen Abandons Prader-Willi Drug, Could Rhythm Offer Hope? | David Holley | 07/28/16 | Boston |
